FutureChem's stock price jumped over 20% in the after-market on the 8th, from 3:40 p.m. to 8 p.m. This is believed to be due to the final results of the Phase 2 clinical trial for the prostate cancer treatment FC705, which showed superior efficacy indicators compared to competitor products.
FutureChem shares were traded at 24,350 won in the after-market at 6:28 p.m. that day, up 19.7% (4,000 won) from the regular market closing price of 20,350 won.
FutureChem announced the contents of the final report of its Phase 2 clinical trial after the regular market closed that day. Both efficacy and safety evaluation indicators showed improved results compared to competitor products.
FutureChem has currently submitted an Investigational New Drug application for Phase 3 clinical trial approval to The Ministry of Food and Drug Safety, and plans to compare the therapeutic effects between a treatment group combining FC705 with standard treatment and a control group applying only the standard treatment.
FutureChem also stated that since FC705 has been designated as an orphan drug, it plans to apply for approval as soon as it receives Phase 3 approval. A FutureChem official noted, "We aim to actively engage in technology transfer discussions with global pharmaceutical companies that requested the Phase 2 results."